Terms: = Germ cell tumor AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Prognosis
972 results:
1. Targeting inflammation in glioblastoma: An updated review from pathophysiology to novel therapeutic approaches.
Alorfi NM; Ashour AM; Alharbi AS; Alshehri FS
Medicine (Baltimore); 2024 May; 103(21):e38245. PubMed ID: 38788009
[TBL] [Abstract] [Full Text] [Related]
2. mRNA markers for survival prediction in glioblastoma multiforme patients: a systematic review with bioinformatic analyses.
Azimi P; Yazdanian T; Ahmadiani A
BMC Cancer; 2024 May; 24(1):612. PubMed ID: 38773447
[TBL] [Abstract] [Full Text] [Related]
3. CDCA3 is a potential biomarker for glioma malignancy and targeted therapy.
Han C; Liu S; Ji Y; Hu Y; Zhang J
Medicine (Baltimore); 2024 May; 103(19):e38066. PubMed ID: 38728485
[TBL] [Abstract] [Full Text] [Related]
4. Antioxidant network-based signatures cluster glioblastoma into distinct redox-resistant phenotypes.
Yang Y; More S; De Smet F; De Vleeschouwer S; Agostinis P
Front Immunol; 2024; 15():1342977. PubMed ID: 38698847
[TBL] [Abstract] [Full Text] [Related]
5. Construction of oxidative phosphorylation-related prognostic risk score model in uveal melanoma.
Zhan Z; Lin K; Wang T
BMC Ophthalmol; 2024 May; 24(1):204. PubMed ID: 38698303
[TBL] [Abstract] [Full Text] [Related]
6. Experimentally validated oxidative stress -associated prognostic signatures describe the immune landscape and predict the drug response and prognosis of SKCM.
Rong D; Su Y; Jia D; Zeng Z; Yang Y; Wei D; Lu H; Cao Y
Front Immunol; 2024; 15():1387316. PubMed ID: 38660305
[TBL] [Abstract] [Full Text] [Related]
7. A multi-omics analysis-based model to predict the prognosis of low-grade gliomas.
Du Z; Jiang Y; Yang Y; Kang X; Yan J; Liu B; Yang M
Sci Rep; 2024 Apr; 14(1):9427. PubMed ID: 38658591
[TBL] [Abstract] [Full Text] [Related]
8. Diffusion- and Perfusion-Weighted MRI Radiomics for Survival Prediction in Patients with Lower-Grade Gliomas.
Park CJ; Kim S; Han K; Ahn SS; Kim D; Park YW; Chang JH; Kim SH; Lee SK
Yonsei Med J; 2024 May; 65(5):283-292. PubMed ID: 38653567
[TBL] [Abstract] [Full Text] [Related]
9. Analysis of the sodium pump subunit ATP1A3 in glioma patients: Potential value in prognostic prediction and immunotherapy.
Lan YL; Zou S; Qin B; Zhu X
Int Immunopharmacol; 2024 May; 133():112045. PubMed ID: 38615384
[TBL] [Abstract] [Full Text] [Related]
10. Development and validation of a multi-modality fusion deep learning model for differentiating glioblastoma from solitary brain metastases.
Shen S; Li C; Fan Y; Lu S; Yan Z; Liu H; Zhou H; Zhang Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Jan; 49(1):58-67. PubMed ID: 38615167
[TBL] [Abstract] [Full Text] [Related]
11. Pathway-based stratification of gliomas uncovers four subtypes with different TME characteristics and prognosis.
Huang R; Han B; Zhang Y; Yang J; Wang K; Liu X; Wang Z
J Cell Mol Med; 2024 Apr; 28(8):e18208. PubMed ID: 38613347
[TBL] [Abstract] [Full Text] [Related]
12. Long noncoding RNA UNC5B-AS1 suppresses cell proliferation by sponging miR-24-3p in glioblastoma multiforme.
Song Y; Chen B; Jiao H; Yi L
BMC Med Genomics; 2024 Apr; 17(1):83. PubMed ID: 38594690
[TBL] [Abstract] [Full Text] [Related]
13. Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of prognosis in Glioma.
Zhuang Y; Chen J; Mai Z; Huang W; Zhong W
J Mol Neurosci; 2024 Apr; 74(2):38. PubMed ID: 38573391
[TBL] [Abstract] [Full Text] [Related]
14. Deciphering cutaneous melanoma prognosis through LDL metabolism: Single-cell transcriptomics analysis via 101 machine learning algorithms.
Xie J; Wu D; Zhang P; Zhao S; Qi M
Exp Dermatol; 2024 Apr; 33(4):e15070. PubMed ID: 38570935
[TBL] [Abstract] [Full Text] [Related]
15. Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines.
Marallano VJ; Ughetta ME; Tejero R; Nanda S; Ramalingam R; Stalbow L; Sattiraju A; Huang Y; Ramakrishnan A; Shen L; Wojcinski A; Kesari S; Zou H; Tsankov AM; Friedel RH
Sci Rep; 2024 Mar; 14(1):7246. PubMed ID: 38538643
[TBL] [Abstract] [Full Text] [Related]
16. GraphMHC: Neoantigen prediction model applying the graph neural network to molecular structure.
Jeong H; Cho YR; Gim J; Cha SK; Kim M; Kang DR
PLoS One; 2024; 19(3):e0291223. PubMed ID: 38536842
[TBL] [Abstract] [Full Text] [Related]
17. Dysregulation of LINC00324 promotes poor prognosis in patients with glioma.
Jin X; Zhu J; Yu H; Shi S; Shen K; Gu J; Yin Z; Yu Z; Wu J
PLoS One; 2024; 19(3):e0298055. PubMed ID: 38530810
[TBL] [Abstract] [Full Text] [Related]
18. Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas.
Song D; Yang Q; Li L; Wei Y; Zhang C; Du H; Ren G; Li H
Front Immunol; 2024; 15():1372113. PubMed ID: 38529286
[TBL] [Abstract] [Full Text] [Related]
19. NPS-2143 inhibit glioma progression by suppressing autophagy through mediating AKT-mTOR pathway.
Nie JL; Li Q; Yin HT; Yang JH; Li M; Li Q; Fan XH; Zhao QQ; Wen ZP
J Cell Mol Med; 2024 Apr; 28(7):e18221. PubMed ID: 38509759
[TBL] [Abstract] [Full Text] [Related]
20. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
Wei X; Zou Z; Zhang W; Fang M; Zhang X; Luo Z; Chen J; Huang G; Zhang P; Cheng Y; Liu J; Liu J; Zhang J; Wu D; Chen Y; Ma X; Pan H; Jiang R; Liu X; Ren X; Tian H; Jia Z; Guo J; Si L
Eur J Cancer; 2024 May; 202():114008. PubMed ID: 38479118
[TBL] [Abstract] [Full Text] [Related]
[Next]
